医学
羟基氯喹
怀孕
磺胺吡啶
来氟米特
类风湿性关节炎
硫唑嘌呤
抗磷脂综合征
不利影响
甲氨蝶呤
不育
重症监护医学
产科
内科学
疾病
血栓形成
传染病(医学专业)
遗传学
生物
溃疡性结肠炎
2019年冠状病毒病(COVID-19)
出处
期刊:Archives of internal medicine
[American Medical Association]
日期:2000-03-13
卷期号:160 (5): 610-619
被引量:242
标识
DOI:10.1001/archinte.160.5.610
摘要
Many rheumatic diseases affect women of childbearing age, and the medications used to treat these diseases may affect conception, pregnancy, fetal development, and lactation. Physicians who care for these women need to be aware of the potential adverse effects of these medications, and which medications can be used safely prior to conception and during pregnancy and lactation. Although reviews of individual classes of medications are available, there is no practical and comprehensive review that summarizes all of this information, and includes anticoagulant drugs and 2 recently approved drugs for rheumatoid arthritis. Women who take cytotoxic drugs should be informed of the risks of impaired fertility and congenital malformations, and must use effective methods of contraception. During pregnancy, nonsteroidal anti-inflammatory agents may be used until the last 6 weeks, and low to moderate doses of corticosteroids are safe throughout pregnancy. Among the disease-modifying agents, sulfasalazine and hydroxychloroquine treatment may be maintained. Cytotoxic drugs may be used after the first trimester to treat life-threatening disease. During lactation, prednisone, sulfasalazine, and hydroxychloroquine may be used cautiously. Women using heparin for treatment of antiphospholipid antibody syndrome should take measures to prevent bone loss. Men taking methotrexate, sulfasalazine, cyclosporine, azathioprine, or leflunomide should be apprised of the possibilities of infertility and teratogenicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI